What Triumph Research Intelligence does

Triumph Research Intelligence (TRI) is a Cambridge, UK-based, privately held software company that builds and sells the OPRA platform — a cloud-based Risk-Based Quality Management (RBQM) suite for clinical trials — to pharmaceutical sponsors and contract research organizations. Founded in 2013 by CEO Duncan Hall, TRI has grown the platform across three interlocking modules: OPRA-CM (Centralized Monitoring, launched 2016 and substantially overhauled in 2025), OPRA-RAM (Risk Assessment & Management, launched 2020), and OPRA-SM (Subject Monitoring, launched 2026 for early-phase and low-volume trials). Collectively these modules automate monitoring workflows, surface risk signals via tailored statistical models, and produce audit-ready documentation aligned to 21 CFR Part 11 and ICH E6(R3). TRI reports 450+ clinical trials running on OPRA globally and claims up to 30% reductions in monitoring costs and trial-efficiency gains; approximately 30% of work is concentrated in oncology studies. Named customers include Worldwide Clinical Trials (running 150 trials on the platform), Roche, IQVIA, Alimentiv, Caidya, Emmes, Klifo, Catalyst, and Advanced Clinical — a mix of top-tier CROs and a major pharma sponsor.

TRI generates revenue primarily through enterprise SaaS subscriptions for the OPRA platform, with additional contribution from implementation, configuration, and training professional services, plus CPD-certified e-Learning licensing (GCP, ICH E8(R1), and Risk Assessment courses). The company sells exclusively via direct enterprise field sales, with 'Book a Demo' CTAs, a savings calculator tool, and consultative quote-based pricing rather than transparent tiers. Distribution is direct-only with no disclosed channel partners, resellers, or marketplace listings; the company operates a remote-first model from its Cambridge headquarters (1 Signet Court, Swanns Road, CB5 8LA), with a US operating subsidiary (Triumph Consultancy Services, Inc) supporting North American commercial activity.

TRI's go-to-market targets pharmaceutical sponsors and CROs through industry events (SCOPE, SCDM, OCT, CRO Summit), webinars, content marketing (RBQM guides, whitepapers, monthly 'The Quality Issue' newsletter), and an active LinkedIn presence. The leadership bench was recently strengthened by the appointment of Jamie Moss — formerly Group COO and CEO of Enterprise Technologies at Calyx (Parexel Informatics) and global operations lead at CRF Health — as Executive Chair, signaling institutional scaling intent. Other executives include COO Tammy Finnigan, Chief Strategy Officer Dale Jessop (two prior eClinical trade sales and one IPO), CTPO Becky Read, CCO Caroline O'Connor, SVP of Sales Tim Collard, and dedicated Heads of Marketing and HR.

Name

Triumph Research Intelligence

Legal name

Triumph Research Intelligence Limited

Website

https://tritrials.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Triumph Research Intelligence is a Cambridge, UK-based SaaS provider of the OPRA Risk-Based Quality Management platform for clinical trials, serving pharmaceutical sponsors and CROs with centralized monitoring, risk assessment, and subject monitoring modules across 450+ trials.

Ownership category

akta.pro rank

Product category

Clinical Trial Risk-Based Monitoring Software

NAICS

Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

akta.pro secondary industries

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Risk-based quality management
• Clinical trial monitoring
• Centralized monitoring software
• Clinical risk assessment
• Pharmaceutical RBQM platform

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. OPRA Platform Subscription: SaaS subscription model providing access to the OPRA platform modules (CM, RAM, SM) for centralized monitoring, risk assessment, and subject monitoring. Revenue generated through recurring subscription fees based on usage scope, study count, or enterprise-wide deployment.
2. e-Learning Services: CPD-certified e-learning courses for GCP training, ICH E8(R1), and Risk Assessment and Controls. Delivered as standalone courses or integrated into LMS systems, generating revenue through course licensing or per-user access fees.
3. Professional Services: Implementation services including onboarding support, custom configuration, training for system admins and super users, and ongoing customer support. Assigned full implementation team to each client with templates, sandbox testing, and walkthroughs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

TRI provides the OPRA platform, a cloud-based Risk-Based Quality Management (RBQM) software suite for clinical trials, comprising OPRA-CM (Centralized Monitoring), OPRA-RAM (Risk Assessment and Management), and OPRA-SM (Subject Monitoring) modules. The platform helps pharmaceutical sponsors and Contract Research Organizations (CROs) reduce monitoring costs, achieve compliance with ICH E6(R3) and 21 CFR Part 11, and proactively manage risks across all trial phases. TRI also offers CPD-certified e-learning courses covering GCP, ICH E8(R1), and Risk Assessment and Controls.

Product overview

Triumph Research Intelligence (TRI) offers OPRA, a unified RBQM platform consisting of three interconnected modules: OPRA-CM (Centralized Monitoring) for trial oversight and risk signal detection, OPRA-RAM (Risk Assessment & Management) for proactive risk identification and mitigation, and OPRA-SM (Subject Monitoring) for subject-level oversight in early-phase studies. The platform is designed to reduce monitoring costs by up to 30% while improving trial quality and patient safety. TRI also provides complementary e-learning training modules (CPD-certified GCP, ICH E8, Risk Assessment courses) and a Savings Calculator tool. The platform is 21 CFR Part 11 compliant and supports all trial phases, with specific expertise in oncology trials (approximately 30% of work).

Differentiator

Problem solved

Functional benefit

Brands

• OPRA-CM: Centralized monitoring platform for clinical trials that delivers dynamic, structured views surfacing evolving risk signals and providing actionable insights.
• OPRA-RAM
• OPRA-SM

Products and services

• OPRA Central Monitoring (OPRA-CM) Centralized monitoring module that connects clinical and operational data in a single intuitive environment, providing dynamic risk signal surfacing, automated workflows, real-time insights, and KRIs/QTLs oversight for pharmaceutical sponsors and CROs.
• OPRA Risk Assessment & Management (OPRA-RAM) Risk assessment and management module that empowers clinical researchers to proactively identify, evaluate, and mitigate risks; includes standardized risk libraries, visual risk dashboards, central activity management, and one-click PDF reports.
• OPRA Subject Monitoring (OPRA-SM) Subject-level monitoring solution designed for early-phase and low-volume clinical trials that displays all visits, adverse events, labs, dosing, and assessments on a single chronological timeline with built-in audit trail and role-based access control.
• OPRA Platform Comprehensive cloud-based RBQM platform encompassing OPRA-CM, OPRA-RAM, and OPRA-SM modules to deliver centralized risk management, monitoring oversight, and subject-level insight across all clinical trial phases for sponsors and CROs.
• TRI e-Learning CPD-certified e-learning platform for clinical trial training covering Good Clinical Practice (GCP), ICH E8(R1), and Risk Assessment and Controls, featuring scenario-based interactive content delivered via role-specific learning pathways for clinical research professionals.

Quantifiable outcome

• Reduce monitoring costs by up to 30%
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

One partnership is on record.

• ACROcoreStrategic or Co-development PartnerTRI collaborates with ACRO (Association of Clinical Research Organizations) as an active participant in industry working groups. TRI references ACRO's RBQM reports and guidelines, and contributes to industry discussions on RBQM adoption and regulatory alignment.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva's Vault CTMS and broader clinical suite compete with TRI for enterprise pharma and CRO spend, with RBQM increasingly folded into its broader platform roadmap.
• Medidata Solutions (Dassault Systèmes): Medidata's Rave platform includes RBQM-adjacent capabilities within one of the industry's broadest clinical trial technology suites, competing with TRI at the enterprise procurement level even though RBQM is not its core focus.
• Oracle Health Sciences: Oracle Clinical One offers unified clinical trial operations including risk-based monitoring, competing as a large-scale enterprise incumbent that can absorb RBQM functionality into broader deals.

Direct peers

• CluePoints: CluePoints is the most directly comparable specialist RBQM and centralized statistical monitoring platform for clinical trials, competing head-to-head with TRI's OPRA-CM and OPRA-RAM modules across the same sponsor and CRO buyer base.
• Signant Health: Signant Health offers an eClinical suite that includes RBQM, eCOA, and patient-centric clinical technology, directly overlapping TRI's RBQM positioning while serving the same pharmaceutical sponsor and CRO customers.
• eClinical Solutions: eClinical Solutions offers the elluminate clinical data platform with RBM/RBQM capabilities, serving biopharma sponsors and CROs with overlapping centralized monitoring and risk-based quality management functionality.

Emerging players

• Cytel: Cytel delivers statistical and clinical analytics services including risk-based monitoring enablement for biopharma, overlapping with TRI in the centralized monitoring and statistical risk analytics layer.
• Saama Technologies: Saama provides AI-driven clinical analytics and operational data platforms that intersect with TRI's RBQM use cases, particularly around risk signal detection and trial oversight.

Others

• Worldwide Clinical Trials: Worldwide Clinical Trials is both a TRI customer and a CRO that offers its own centralized monitoring and RBQM services, representing the buyer side of TRI's market as well as a potential competitor in services.
• WCG: WCG provides clinical trial services and technology with risk-based monitoring capabilities that intersect with TRI's platform, serving many of the same sponsors and CROs as a broader clinical services partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tri-the-rbqm-experts
• Xx.com/TRI_OPRA_RBM

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triumph Research Intelligence